SKLB-610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB-610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10µM in biochemical kinase assays. SKLB-610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity. Its potential to be a candidate of anticancer agent is worth being further investigated.
Buffer:
Powder
CAS Number:
[1125780-41-7]
* VAT and and shipping costs not included. Errors and price changes excepted
